Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Stocks to Love in 2026

View original at nasdaq.com
Stocks to Love in 2026 In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Why space is worth watching in 2026.Opportunities in healthcare.How Hims & Hers is disrupting the healthcare industry To catch full episodes of all The Motley Fool's free podcasts, check out our podca…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Healthcare is a market that desperately needs disruption, but it's also between regulation and it is life or death

    80% confidence

  • Expected to move toward profitability in 2026

    80% confidence

  • Discussed data centers in space with solar power opportunity, more than 5 years away

    80% confidence

  • AI can absorb more real-time patient data than human doctors, such as Garmin watch health data integration

    80% confidence

  • Space investments are high-risk, high-reward

    80% confidence

  • AI has potential to remember/process more medical information than single human physician

    80% confidence

  • Rocket Lab wants to get Neutron launch right the first time, unlike SpaceX's iterative explosion approach

    80% confidence

  • Raised concerns about TransMedics Medicare reimbursement

    80% confidence

  • Prefers Rocket Lab over SpaceX, even if SpaceX was public

    80% confidence

  • Redwire is owning the fundamental building blocks if we're going to have a Golden Age in space

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com